Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation

被引:5
|
作者
Seo, Songyi [1 ]
Kim, Mi-Kyung [2 ]
Kim, Ryul-, I [1 ]
Yeo, Yeongju [1 ]
Kim, Koung Li [1 ]
Suh, Wonhee [1 ]
机构
[1] Chung Ang Univ, Coll Pharm, Dept Globa & Innovat Drug, Seoul 06974, South Korea
[2] Dong A ST Co Ltd, Drug Discovery Res Labs, Gyeonggi Do 17073, South Korea
来源
EXPERIMENTAL AND MOLECULAR MEDICINE | 2020年 / 52卷 / 10期
基金
新加坡国家研究基金会;
关键词
DIABETIC-RETINOPATHY; IV; NEOVASCULARIZATION; PHOSPHORYLATION; MIGRATION; COMPLEX; MOUSE; MODEL; DPP4; MICE;
D O I
10.1038/s12276-020-00512-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Retinal disease: How anti-diabetic drug can help eyes Pathological retinal angiogenesis, the damaging formation of new blood vessels in the retina, which is associated with various diseases including diabetes, could be reduced using the anti-diabetic drug evogliptin to inhibit the effects of a vascular growth factor. Researchers in South Korea led by Wonhee Suh and Koung Li Kim at Chung-Ang University in Seoul investigated the molecular mechanism underlying evogliptin's effects. In studies using mice and cultured human cells they found that evogliptin inhibited the activation of signaling molecules that mediate the effects of vascular endothelial growth factor. They also identified an enzyme in the signaling pathway that is directly inhibited by evogliptin. The results offer molecular level insights into the additional benefit gained from using evogliptin to treat diabetes, distinct from the drug's established effects in lowering blood glucose. Dipeptidyl peptidase-4 (DPP-4) inhibitors are used for the treatment of type 2 diabetes mellitus (DM). Recent studies have shown that beyond their effect in lowing glucose, DPP-4 inhibitors mitigate DM-related microvascular complications, such as diabetic retinopathy. However, the mechanism by which pathological retinal neovascularization, a major clinical manifestation of diabetic retinopathy, is inhibited is unclear. This study sought to examine the effects of evogliptin, a potent DPP-4 inhibitor, on pathological retinal neovascularization in mice and elucidate the mechanism by which evogliptin inhibits angiogenesis mediated by vascular endothelial growth factor (VEGF), a key factor in the vascular pathogenesis of proliferative diabetic retinopathy (PDR). In a murine model of PDR, an intravitreal injection of evogliptin significantly suppressed aberrant retinal neovascularization. In human endothelial cells, evogliptin reduced VEGF-induced angiogenesis. Western blot analysis showed that evogliptin inhibited the phosphorylation of signaling molecules associated with VEGF-induced cell adhesion and migration. Moreover, evogliptin substantially inhibited the VEGF-induced activation of adenosine 5 '-diphosphate ribosylation factor 6 (Arf6), a small guanosine 5 '-triphosphatase (GTPase) that regulates VEGF receptor 2 signal transduction. Direct activation of Arf6 using a chemical inhibitor of Arf-directed GTPase-activating protein completely abrogated the inhibitory effect of evogliptin on VEGF-induced activation of the angiogenic signaling pathway, which suggests that evogliptin suppresses VEGF-induced angiogenesis by blocking Arf6 activation. Our results provide insights into the molecular mechanism of the direct inhibitory effect of the DPP-4 inhibitor evogliptin on pathological retinal neovascularization. In addition to its glucose-lowering effect, the antiangiogenic effect of evogliptin could also render it beneficial for individuals with PDR.
引用
收藏
页码:1744 / 1753
页数:10
相关论文
共 46 条
  • [41] 3,3'-Diinolylmethane inhibits vascular endothelial growth factor-induced activation of p44/p42 mitogen-activated protein kinase in HUVECs and angiogenesis
    Chang, XF
    Firestone, GL
    Bjeldanes, LF
    FASEB JOURNAL, 2005, 19 (05): : A994 - A994
  • [42] Isoprostanes Inhibit Vascular Endothelial Growth Factor-Induced Endothelial Cell Migration, Tube Formation, and Cardiac Vessel Sprouting In Vitro, As Well As Angiogenesis In Vivo via Activation of the Thromboxane A2 Receptor A Potential Link Between Oxidative Stress and Impaired Angiogenesis
    Benndorf, Ralf A.
    Schwedhelm, Edzard
    Gnann, Anke
    Taheri, Raihana
    Kom, Ghainsom
    Didie, Michael
    Steenpass, Anna
    Erguen, Sueleyman
    Boeger, Rainer H.
    CIRCULATION RESEARCH, 2008, 103 (09) : 1037 - U302
  • [43] Dipeptidyl peptidase 4 inhibitor attenuates obesity-induced myocardial fibrosis by inhibiting transforming growth factor-β1 and Smad2/3 pathways in high-fat diet-induced obesity rat model
    Hong, Seul-Ki
    Choo, Eun-Ho
    Ihm, Sang-Hyun
    Chang, Kiyuk
    Seung, Ki-Bae
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 76 : 42 - 55
  • [44] Dipeptidyl peptidase 4 inhibitor attenuates obesity-induced myocardial fibrosis by inhibiting tissue growth factor-beta and Smad2/3 pathways in high-fat diet-induced obesity rat model
    Ihm, Sang-Hyun
    Hong, Seul Ki
    Chang, Kiyuk
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (16) : C26 - C26
  • [45] The Farnesyltransferase Inhibitor LB42708 Suppresses Vascular Endothelial Growth Factor-Induced Angiogenesis by Inhibiting Ras-dependent Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase/Akt Signal Pathways
    Kim, Chun-Ki
    Choi, Yoon Kyung
    Lee, Hansoo
    Ha, Kwon-Soo
    Won, Moo-Ho
    Kwon, Young-Guen
    Kim, Young-Myeong
    MOLECULAR PHARMACOLOGY, 2010, 78 (01) : 142 - 150
  • [46] Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1α expression through activation of AKT and P70S6K1 in human ovarian cancer cells
    Liu, Ling-Zhi
    Hu, Xiao-Wen
    Xia, Chang
    He, Jie
    Zhou, Qiong
    Shi, Xianglin
    Fang, Jing
    Jiang, Bing-Hua
    FREE RADICAL BIOLOGY AND MEDICINE, 2006, 41 (10) : 1521 - 1533